At a glance
- Originator Bristol-Myers Squibb
- Class Cytostatic antibiotics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 Feb 2001 Profile reviewed but no significant changes made
- 06 Oct 1997 No-Development-Reported for Cancer in USA (Unknown route)
- 25 May 1995 Preclinical development for Cancer in USA (Unknown route)